Tixagevimab and Cilgavimab (Evusheld™) Prophylaxis Prevents Breakthrough COVID-19 Infections in Immunosuppressed Population: 6-Month Prospective Study.

Dejan Jakimovski Svetlana P EckertOmid MirmosayyebSangharsha ThapaPenny PenningtonDavid HojnackiBianca Weinstock-Guttman

Published in: Vaccines (2023)

In pwNID treated with immunosuppressive therapies, tixagevimab and cilgavimab (Evusheld™) significantly reduced the numbers and severity of breakthrough COVID-19 infections during the Omicron (BA.2-BA.5 variants) wave.

Keyphrases

coronavirus disease
sars cov
copy number